GET TO KNOW USAt A Glance
Bright Green Corporation has always stood at the forefront of pharmaceutical innovation: first as a federally-authorized grower, manufacturer, and distributor of medical-grade cannabinoid products, and now positioned to become the largest DEA-approved domestic producer and manufacturer of plant-based drugs and Active Pharmaceutical Ingredients (APIs).*
Recent expansions and the redesign of its cutting-edge 1 million+ square foot research and development facility in Grants, New Mexico, signify Bright Green’s commitment to meeting the growing demand for plant-based drugs in the U.S. In a groundbreaking move, they are set to become the only regulated company capable of substantially alleviating the current U.S. dependency on foreign drug imports, exceeding $10 billion annually.
While maintaining its pioneering status in the cannabis industry, Bright Green’s focus has broadened to address the critical need for domestic plant-based drug production, showcasing their dedication to innovation and meeting evolving market demands.
With an unwavering commitment to regulatory compliance, Bright Green has continuously met all federal and state guidelines and requirements as it moves towards finalized DEA approval, opening the door for a massive revenue share of the $27.97B domestic plant-based drug market.
Governed by a board of industry veterans, specialists, and innovative scientists, Bright Green has its sights set on securing lucrative government contracts to drive their next evolution, including the launch of an unprecedented EB-5 offering in partnership with Asia Capital Pioneers Group (ACPG)
